相关实验视频

Updated: Jul 14, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

PRC2介导的KLF2下调:在瘤进展过程中的治疗和诊断轴

Negin Taghehchian¹, Amirhosein Maharati^1,2, Iman Akhlaghipour²

¹Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Cancer cell international

|October 8, 2023

概括

克鲁佩尔样因子2 (KLF2) 作为瘤抑制剂,经常被非编码RNAs抑制. 向KLF2可以提供一种新的治疗策略,以减少癌症复发并最大限度地减少副作用.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

标准的癌症治疗方法,如手术和化疗-放射治疗,往往导致瘤复发.
针对性疗法,如单克隆抗体,显示出希望,但可能会引起副作用,因为生长因子在正常细胞中的重要作用.
在癌症治疗中,需要更具体的治疗点,副作用较少.

研究的目的:

审查克鲁佩尔样因子2 (KLF2) 在癌症进展,入侵和其作为治疗点的潜力的分子机制.
阐明非编码RNAs (ncRNAs) 如何调节瘤中的KLF2功能.
突出KLF2作为潜在的诊断和治疗目标,以减少瘤复发.

主要方法:

对KLF2功能在癌症中的现有文献的综述.
分析涉及KLF2,非编码RNA和多抑制复合体2 (PRC2) 的分子机制.
讨论KLF2作为瘤抑制剂的作用及其在各种癌症中的放松调节.

主要成果:

KLF2作为瘤抑制剂起作用,其活性经常被ncRNAs抑制.
ncRNAs通过招募多抑制复合体2 (PRC2) 来抑制KLF2.
KLF2的放松调节与许多瘤的进展和入侵有关.

结论:

KLF2是细胞过程的关键调节剂,并作为瘤抑制剂.
通过ncRNAs抑制KLF2是瘤发育的关键机制.
KLF2代表了一个有前途的分子标,用于开发具有潜在减少副作用的新型,特定的癌症疗法.

关键词:

癌症癌症癌症癌症诊断诊断诊断诊断诊断在KLF2KLF2KLF2 标记器标记器标记器多复合体复合体是多复合体.有针对性的治疗.瘤抑制剂是一种瘤抑制剂.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...